PLI Scheme gets encouraging response from pharma and medical device industry; closes on 30 Nov

New Delhi, Nov 28 (KNN) Production Linked Incentive (PLI) Scheme for Bulk Drugs and Medical Devices have received a very encouraging response fr0m the pharmaceutical and medical device industry, ministry of Chemicals and Fertilizers stated on Friday.
The PLI Scheme for Bulk Drugs has received 247 registrations across all four categories of products out of which a maximum of 136 applicants will be selected under the Scheme.
Similarly, the PLI Scheme for Medical Devices has received 28 registrations across all four target segments out of which a maximum of 28 applicants will be selected under the Scheme. IFCI Ltd. is the Project Management Agency for the schemes and all the applications are being received on its online portal.
The last date of filing the application under both the schemes is 30.11.2020.
Current and prospective registrants are advised that in view of bank holidays fr0m 28.11.2020 to 30.11.2020, the payment of application fee may be done through the NEFT mode.
The details of the bank accounts are mentioned in the respective guidelines. The team of IFCI Ltd will be available till last date of applications on the contact details mentioned on their website, to assist the applicants.
The PLI Scheme for Bulk Drugs and for Medical Devices was approved by the Government on 20.03.2020. The guidelines for implementation of both the schemes were issued on 27.07.2020 and were revised later based on the feedback received fr0m the industry. The revised guidelines were issued on 29.10.2020.
New Delhi, Jan 16 (KNN) Reacting to December 2020 export figures, Federation of Indian Export…
New Delhi, Jan 14 (KNN) Ministry of Steel in association with the Indian Steel Association…
New Delhi, Jan 14 (KNN) The third phase of Pradhan Mantri Kaushal Vikas Yojana (PMKVY…
New Delhi, Jan 11 (KNN) The Federation of Automobile Dealers Associations (FADA) on Monday said…
New Delhi, Jan 11 (KNN) National Committee on Textiles & Clothing (NCTC) has appealed to…